151 related articles for article (PubMed ID: 29934684)
1. Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada.
Cheung WY; White MK; Bayliss MS; Stroupe A; Lovley A; King-Kallimanis BL; Lasch K
Support Care Cancer; 2019 Jan; 27(1):219-227. PubMed ID: 29934684
[TBL] [Abstract][Full Text] [Related]
2. Humanistic burden of disease for patients with advanced melanoma in Canada.
Cheung WY; Bayliss MS; White MK; Stroupe A; Lovley A; King-Kallimanis BL; Lasch K
Support Care Cancer; 2018 Jun; 26(6):1985-1991. PubMed ID: 29322243
[TBL] [Abstract][Full Text] [Related]
3. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
4. COPD-related fatigue: Impact on daily life and treatment opportunities from the patient's perspective.
Kouijzer M; Brusse-Keizer M; Bode C
Respir Med; 2018 Aug; 141():47-51. PubMed ID: 30053971
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors.
Mamoor M; Postow MA; Lavery JA; Baxi SS; Khan N; Mao JJ; Rogak LJ; Sidlow R; Thom B; Wolchok JA; Korenstein D
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152222
[TBL] [Abstract][Full Text] [Related]
6. Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?
Wong A; Billett A; Milne D
Oncologist; 2019 Nov; 24(11):e1190-e1196. PubMed ID: 31015314
[TBL] [Abstract][Full Text] [Related]
7. Quality of life patient-reported outcomes for locally advanced cutaneous melanoma.
Weitman ES; Perez M; Thompson JF; Andtbacka RHI; Dalton J; Martin ML; Miller T; Gwaltney C; Sarson D; Wachter E; Zager JS
Melanoma Res; 2018 Apr; 28(2):134-142. PubMed ID: 29261570
[TBL] [Abstract][Full Text] [Related]
8. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
[TBL] [Abstract][Full Text] [Related]
9. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
Reddy SB; Possick JD; Kluger HM; Galan A; Han D
J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab-induced Guillain-Barré Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.
Kelly Wu W; Broman KK; Brownie ER; Kauffmann RM
J Immunother; 2017 Jun; 40(5):196-199. PubMed ID: 28452849
[TBL] [Abstract][Full Text] [Related]
14. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
15. Burden of living with multiple concurrent symptoms in patients with end-stage renal disease.
Ng MSN; Wong CL; Ho EHS; Hui YH; Miaskowski C; So WKW
J Clin Nurs; 2020 Jul; 29(13-14):2589-2601. PubMed ID: 32279368
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.
Jain V; Mohebtash M; Rodrigo ME; Ruiz G; Atkins MB; Barac A
J Immunother; 2018 Sep; 41(7):332-335. PubMed ID: 29965858
[TBL] [Abstract][Full Text] [Related]
17. Activity and advanced cancer: A grounded theory.
Lowe SS; Milligan C; Brearley SG
Palliat Med; 2020 Feb; 34(2):231-244. PubMed ID: 31752602
[TBL] [Abstract][Full Text] [Related]
18. "Lower abdominal pains, as if I was being squeezed…in a clamp": A Qualitative Analysis of Symptoms, Patient-Perceived Side Effects and Impacts of Ovarian Cancer.
Martin ML; Halling K; Eek D; Reaney M
Patient; 2020 Apr; 13(2):189-200. PubMed ID: 31691205
[TBL] [Abstract][Full Text] [Related]
19. A Novel Patient-Derived Conceptual Model of the Impact of Celiac Disease in Adults: Implications for Patient-Reported Outcome and Health-Related Quality-of-Life Instrument Development.
Leffler DA; Acaster S; Gallop K; Dennis M; Kelly CP; Adelman DC
Value Health; 2017 Apr; 20(4):637-643. PubMed ID: 28408006
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis.
Li J; Gu J
Immunotherapy; 2018 Nov; 10(15):1293-1302. PubMed ID: 30474476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
